CD34 and prostate cancer: In the present study, the rationale for using these particular markers is that immunostaining of CD31 (endothelial cell protein) and CD34 (vascular endothelial cell protein and neo angiogenesis) have been reported to enable accurate assessment of microvessel density in prostate cancer subjects (Miyata et al., 2015).